PharmaJet

PharmaJet develops and commercializes needle-free precision delivery systems for administering vaccines and medications. It has two approved and commercialized products: 1) PharmaJet Tropis, a needle-free device for intradermal (ID) injections, and 2) PharmaJet Stratis, a needle-free injector that delivers medications and vaccines intramuscularly or subcutaneously, including needle-free flu shots. In March 2011, the FDA approved PharmaJet's 0.1 ml ID needle-free injection system, allowing it to market the first FDA-cleared needle-free alternative to the traditional needle-based "Mantoux'' technique for tuberculosis and rabies vaccines.

PharmaJet's systems use a narrow, high-velocity fluid injection to deliver vaccines and medications without needles. This technology offers several benefits, including increased vaccine effectiveness, reduced dosage requirements, and a better experience for patients and caregivers. The systems are designed to be safe, fast, and easy to use, making them suitable for mass vaccination campaigns and routine immunization programs.

Key customers and partnerships

As of July 2024, PharmaJet partnered with over 80 pharmaceutical, biotechnology, and academic institutions. The company had 100+ clinical studies in progress and 65+ completed. Major pharmaceutical partners include Merck, Takeda, and Invectys.

PharmaJet has formed several key partnerships to advance its needle-free injection technology. In May 2020, it partnered with Abnova to use PharmaJet's needle-free injection system for delivering an mRNA vaccine against SARS-CoV-2, aiming to enhance the protective antibody response against Covid-19. In March 2022, PharmaJet collaborated with Immunomic Therapeutics to start a Phase I clinical study of the plasmid DNA vaccine ITI-3000 in patients with Merkel cell carcinoma, utilizing the Stratis needle-free injection system. Additionally, in April 2023, PharmaJet partnered with Genoskin to explore the benefits of its ID precision delivery systems for vaccine delivery, leveraging Genoskin’s expertise in human skin immunology.

PharmaJet's technology is also used in collaborations with the WHO and the Bill and Melinda Gates Foundation to improve global vaccination efforts, particularly in developing countries like Somalia, Nigeria, Pakistan, Cuba, and The Gambia. These collaborations aim to increase the accessibility and efficacy of vaccines, especially through door-to-door immunization campaigns.